Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet …
Biotechnology
US, South San Francisco [HQ]
Strategy & Leadership
All directors and officers of Vaxart, Inc. are sourced directly from the SEC or manually.
For the SEC we either use the Form 3/4/5 or, even better extract the compensation for each leader out of the audited proxy statement (DEF-14A).
Each datapoint refers the most recent appearance of the corresponding person.
Officers & BofD Beta
For the SEC we either use the Form 3/4/5 or, even better extract the compensation for each leader out of the audited proxy statement (DEF-14A).
Total Compensation
Shows the total compensation per mentioned executive and board director.Each datapoint refers the most recent appearance of the corresponding person.
- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position | Research | Last Appearance | ||
---|---|---|---|---|
Lee Phillip E
Chief Financial Officer
|
12/17/24 [Form 4]
|
|||
Tucker Sean
SVP, Chief Scientific Officer
|
04/01/24 [Form 4]
|
|||
Cummings James F.
Chief Medical Officer
|
04/01/24 [Form 4]
|
|||
Berg Edward B
SVP, General Counsel
|
03/20/24 [Form 4]
|
|||
Lo Steven
President, Chief Exec Officer
Also inside the BofD
|
03/20/24 [Form 4]
|
|||
Floroiu Cezar Andrei
President, Chief Exec Officer
Also inside the BofD
|
03/21/23 [Form 4]
|
|||
Ahmad Fuad
Interim CFO
|
06/23/22 [Form 4]
|
Board of Directors (BofD)
Name & Position | Research | Last Appearance | ||
---|---|---|---|---|
Watson W. Mark
Director
|
06/20/24 [Form 4]
|
|||
Wheadon David E.
Director
|
06/12/24 [Form 4]
|
|||
Finney Michael J.
Director
|
06/12/24 [Form 4]
|
|||
Heron Elaine J
Director
|
06/12/24 [Form 4]
|
|||
Yedid Robert A.
Director
|
06/12/24 [Form 4]
|
|||
Davis Todd C
Director
|
08/08/22 [Form 4]
|
|||
Cherrington Julie M
Director
|
08/08/22 [Form 4]
|